Global Urticaria Market, By Type (Acute Urticaria, Chronic Urticaria), Drug Class (Antihistamines, Anti-inflammation Medications, Antidepressants, Monoclonal Antibodies, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Urticaria Market Analysis and Size
The global urticaria market is expected to witness significant growth during the mentioned forecast period. Rising markets and huge investment in R&D are the major factors that are responsible for the growth of this market. Growing cases of urticaria market also creates an opportunity for the pharmaceutical companies to develop novel therapies and promising pipeline drugs. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global urticaria market in the forecast period 2022-2029. The expected CAGR of global urticaria market is tend to be around 15.0% in the mentioned forecast period. The market was valued at USD 2.45 billion in 2021, and it would grow upto USD 7.5 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Urticaria are characterized as raised, swollen, itchy, and red plums that appear on the skin which can be of different sizes. It can be caused as a result of indoor as well as outdoor allergens reactions or certain infections.
Urticaria Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Acute Urticaria, Chronic Urticaria), Drug Class (Antihistamines, Anti-inflammation Medications, Antidepressants, Monoclonal Antibodies, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Amneal Pharmaceuticals, Inc. (U.S.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Novartis AG (Switzerland)., Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Dr. Reddy's Laboratories Ltd (India), Mylan N.V (U.S.)
|
|
Market Opportunities
|
|
Global Urticaria Market Dynamics
Drivers
- Patient Awareness
Increasing awareness of hypersensitivity is increasing the demand for the treatment of chronically induced urticaria. Patients are now more active about their health and are ready to seek medical advice early. Improving literacy rates play an important role in the general patient's perception of the treatment of chronically induced urticaria.
Opportunities
- Rising Incidence of Utricaria
High prevalence of urticaria is one of the boosting factors for the growth in the global chronic spontaneous urticaria market. As per the American Academy of Allergy, Asthma and Immunology, around 20% of the people are infected with chronic urticaria in the U.S.
- Advanced Clinical Research and Technological Advancement
The development of new targeted therapies such as omalizumab for the treatment of chronic urticaria is expected to drive the market in the near future. In Poland, a study of 1091 patients with chronic urticaria was conducted in 2019 to assess the epidemiological and clinical features of chronic urticaria. Chronic spontaneous urticaria has been reported to cause chronic urticaria about twice as likely as chronic inducible urticaria.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to perform the treatment methods could curb the growth of the global urticaria market over a forecast period.
- High Cost
The huge expenditure required for the treatment surely hamper the market growth.
This global urticaria market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global urticaria market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Urticaria Market
Considering the present scenario, COVID-19 has an unprecedented global public health crisis that left a major impact on every business. Its long-term repercussions are expected to accelerate market growth during the forecast period.
In the post-pandemic era, The urticaria market is estimated to be positively impacted attributing to the increasing number of chronic spontaneous urticarial in the COVID infected patients.
Global Urticaria Market Scope
The global urticaria market is segmented on the basis of type, drug class, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Acute Urticaria
- Chronic Urticaria
Drug Class
- Antihistamines
- Anti-inflammation Medications
- Antidepressants
- Monoclonal Antibodies
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Urticaria Market Regional Analysis/Insights
The global urticaria market is analysed and market size insights and trends are provided by type, drug class, route of administration, end-user and distribution channel as referenced above.
The major countries covered in the global urticaria market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for Urticaria market due to the major leaders in R&D activities, unhealthy life-style such as consumption of alcohol.
Asia-Pacific dominates the market due to the large number of generic manufacturer, developing healthcare facilities, and rise in government initiatives.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Urticaria Market Share Analysis
The global urticaria market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global urticaria market
Key players operating in the global urticaria market include:
- Johnson & Johnson Private Limited (U.S.)
- Amneal Pharmaceuticals, Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Dr. Reddy's Laboratories Ltd (India)
- Mylan N.V (U.S.)
SKU-